We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Studies set to assess pamrevlumab in IPF have been ...
Results from the FIBRONEER-ILD trial showed nerandomilast significantly slowed lung function decline in patients with PPF compared with placebo. The Food and Drug Administration (FDA) has expanded the ...
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and ...
Among patients with idiopathic pulmonary fibrosis, inhaled treprostinil was associated with a smaller decline in forced vital capacity (FVC) and fewer episodes of clinical worsening than placebo over ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results